TABLE 1.

Demographic and baseline characteristic (safety population)

Characteristicc	Value for ST-246 treatment
	Placebo (n = 6)	250 mg (n = 8)	400 mg (n = 8)	800 mg (n = 8)	Total active treatment (250-800 mg) (n = 24)
Gender [no. (%)]
Male	4 (66.7)	5 (62.5)	4 (50.0)	7 (87.5)	16 (66.7)
Female	2 (33.3)	3 (37.5)	4 (50.0)	1 (12.5)	8 (33.3)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Race [no. (%)]
White	4 (66.7)	7 (87.5)	6 (75.0)	4 (50.0)	17 (70.8)
Black	2 (33.3)	0 (0.0)	2 (25.0)	4 (50.0)	6 (25.0)
Asian	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
American Indian or Alaska native	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Native Hawaiian or other Pacific islander	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other	0 (0.0)	1 (12.5)	0 (0.0)	0 (0.0)	1 (4.2)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity [no. (%)]
Hispanic or Latino	2 (33.3)	3 (37.5)	3 (37.5)	0 (0.0)	6 (25.0)
Not Hispanic or Latino	4 (66.7)	5 (62.5)	5 (62.5)	8 (100.0)	18 (75.0)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Agea (yr)
n	6	8	8	8	24
Mean	34.8	36.5	27.6	37.5	33.9
SD	8.9	8.2	7.8	7.6	8.8
Median	36.5	37.5	25.5	35.5	34.5
Min-Max	24-47	23-47	18-39	29-49	18-49
Missing	0	0	0	0	0
Wtb (kg)
n	6	8	8	8	24
Mean	74.72	75.09	70.99	86.76	77.61
SD	14.63	15.28	15.34	11.95	15.26
Median	72.42	76.80	70.20	92.50	74.50
Min-Max	55.9-95.5	53.6-102.1	54.1-104.0	66.4-100.0	53.6-104.0
Missing	0	0	0	0	0
Htb (cm)
n	6	8	8	8	24
Mean	174.5	170.1	168.0	178.3	172.1
SD	5.8	11.2	11.2	6.1	10.4
Median	174.5	174.0	166.0	178.5	174.0
Min-Max	167-182	151-181	155-191	168-186	151-191
Missing	0	0	0	0	0
Body mass indexb (kg/m2)
n	6	8	8	8	24
Mean	24.4	25.9	24.9	27.2	26.0
SD	4.0	4.3	2.4	2.6	3.2
Median	24.6	26.2	25.1	27.5	26.2
Min-Max	19-29	18-31	20-29	22-30	18-31
Missing	0	0	0	0	0

^aAge = integer ([screening visit date − birth date]/365.25).

^bMeasurement at screening.

^cPercentages are based on the number of subjects in each group. Min-Max, range of minimum to maximum.